Argenx (NASDAQ:ARGX) announced today that its pivotal ADHERE study on VYVGART® Hytrulo has been published in The Lancet Neurology.
This study is the largest clinical trial to date investigating chronic inflammatory demyelinating polyneuropathy (CIDP), a severe autoimmune disorder.
"Since its approval in June, VYVGART Hytrulo is already transforming the lives of patients with CIDP," said Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx.
The ADHERE study demonstrated substantial benefits of VYVGART Hytrulo, including a 61% reduction in the risk of relapse and rapid onset of action.
Additionally, 99% of trial participants opted for an open-label extension.
Meanwhile, VYVGART Hytrulo remains the first and only FDA-approved neonatal Fc receptor blocker for treating CIDP.
Following the announcement, Argenx's share price remained steady at $529.06.